Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 6/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | GAA | P10253 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | BMP1 | P13497 | 1/20 | 0.64 |
| ▸ | MMP2 | P08253 | 3/20 | 0.63 |
| ▸ | MMP9 | P14780 | 2/20 | 0.63 |
| ▸ | MMP8 | P22894 | 2/20 | 0.63 |
| ▸ | TACR1 | P25103 | 2/20 | 0.63 |
| ▸ | MMP1 | P03956 | 1/20 | 0.60 |
| ▸ | MME | P08473 | 2/20 | 0.60 |
| ▸ | ECE1 | P42892 | 2/20 | 0.60 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8019332 | 0.92 | NMBR (0.71) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL12706375 | 0.91 | NMBR (0.75) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL5380441 | 0.90 | NMBR (0.74) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL14595064 | 0.90 | NMBR (0.74) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL8257108 | 0.89 | MAPT (0.89) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL19102167 | 0.89 | MAPT (0.89) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL5189454 | 0.89 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL14595066 | 0.89 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL2417039 | 0.89 | NMBR (0.90) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL5189427 | 0.89 | NMBR (0.76) | NMBRMAPTGAAHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1778637-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006012256-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | NMBR 1470/4885MAPT 192/4885GAA 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.